Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

121 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Design and rationale of the ATHENA study--A 12-month, multicentre, prospective study evaluating the outcomes of a de novo everolimus-based regimen in combination with reduced cyclosporine or tacrolimus versus a standard regimen in kidney transplant patients: study protocol for a randomised controlled trial.
Sommerer C, Suwelack B, Dragun D, Schenker P, Hauser IA, Nashan B, Thaiss F. Sommerer C, et al. Among authors: thaiss f. Trials. 2016 Feb 17;17:92. doi: 10.1186/s13063-016-1220-9. Trials. 2016. PMID: 26888217 Free PMC article. Clinical Trial.
An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients.
Sommerer C, Suwelack B, Dragun D, Schenker P, Hauser IA, Witzke O, Hugo C, Kamar N, Merville P, Junge M, Thaiss F, Nashan B; Athena Study Group. Sommerer C, et al. Among authors: thaiss f. Kidney Int. 2019 Jul;96(1):231-244. doi: 10.1016/j.kint.2019.01.041. Epub 2019 Feb 27. Kidney Int. 2019. PMID: 31027892 Free article. Clinical Trial.
Effect of everolimus-based drug regimens on CMV-specific T-cell functionality after renal transplantation: 12-month ATHENA subcohort-study results.
Hauser IA, Marx S, Sommerer C, Suwelack B, Dragun D, Witzke O, Lehner F, Schiedel C, Porstner M, Thaiss F, Neudörfl C, Falk CS, Nashan B, Sester M. Hauser IA, et al. Among authors: thaiss f. Eur J Immunol. 2021 Apr;51(4):943-955. doi: 10.1002/eji.202048855. Epub 2020 Dec 28. Eur J Immunol. 2021. PMID: 33306229 Free article.
Preformed T cell alloimmunity and HLA eplet mismatch to guide immunosuppression minimization with tacrolimus monotherapy in kidney transplantation: Results of the CELLIMIN trial.
Bestard O, Meneghini M, Crespo E, Bemelman F, Koch M, Volk HD, Viklicky O, Giral M, Banas B, Ruiz JC, Melilli E, Hu L, van Duivenvoorden R, Nashan B, Thaiss F, Otto NM, Bold G, Stein M, Sefrin A, Lachmann N, Hruba P, Stranavova L, Brouard S, Braudeau C, Blancho G, Banas M, Irure J, Christakoudi S, Sanchez-Fueyo A, Wood KJ, Reinke P, Grinyó JM. Bestard O, et al. Among authors: thaiss f. Am J Transplant. 2021 Aug;21(8):2833-2845. doi: 10.1111/ajt.16563. Epub 2021 Apr 15. Am J Transplant. 2021. PMID: 33725408 Free article. Clinical Trial.
121 results